• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
CLSN

CLSN

Imunon, Inc.

NASDAQHealthcareBiotechnologyUS

USD1.95

-0.01 (-0.68%)

Company Profile

CEO

Michael Tardugno

IPO Date

1993-10-27

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$1.96

Prev. Close

$1.96

Day Low

$1.93

Day High

$1.99

Market Cap

$0.01B

Volume

0.06M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

25.1%

Avg Negative

3.8%

Avg Neutral

71.2%

News Feed

Celsion Corporation (CLSN) CEO Michael Tardugno on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/12/2021·↓ negative

Celsion Corporation Establishes Wholly Owned Subsidiary to Manage Investigator-Sponsored Development of ThermoDox®

GlobeNewsWire·6/23/2021·↑ positive

Celsion Corporation Enters into $10 Million Strategic Loan Facility with Silicon Valley Bank

GlobeNewsWire
·6/21/2021
·↑ positive

CELSION CORPORATION ANNOUNCES ADJOURNMENT OF ANNUAL MEETING

GlobeNewsWire·6/4/2021·↑ positive

Celsion Corporation Urges All Shareholders to Vote at the 2021 Annual Meeting to be Held on Friday June 4, 2021

GlobeNewsWire·5/27/2021·↑ positive

Celsion Corporation (CLSN) CEO Michael Tardugno on Q1 2021 Results - Earnings Call Transcript

Seeking Alpha·5/14/2021·↓ negative

Celsion Corporation Reports First Quarter 2021 Financial Results and Provides Business Update

GlobeNewsWire·5/14/2021·↑ positive

Celsion Corporation to Hold First Quarter 2021 Financial Results and Business Update Conference Call on Friday, May 14, 2021

GlobeNewsWire·5/7/2021·↑ positive

CELSION CORPORATION ANNOUNCES CLOSING OF $15 MILLION REGISTERED DIRECT OFFERING

GlobeNewsWire·4/5/2021·↓ negative

Celsion's Ovarian Cancer Immunotherapy Shows 41% Improvement In R0 Resection Rates

Benzinga·4/1/2021·↑ positive